Valence 로고
인기
로그인

관심목록에 추가

DexCom Inc.

NasdaqGS: DXCM · 실시간 가격 · USD
90.63
+1.03 (1.15%)
종가 기준: Aug 18, 2026, 3:59 PM

DexCom Inc. (DXCM) Stock Price, Analysis & Data

1.15%
매수호가71.2
시가총액34.2B
매출 (ttm)4.97B
순이익 (ttm)999.7M
베타1.41
EPS (ttm)2.53
P/E (ttm)35.82
선행 P/E29.01
P/B (ttm)13.05
P/S (ttm)6.88
Earnings DateOct 29, 2026
매도호가107.46
거래량149,453
평균 거래량 (20일)5,393,054
시가90.30
전일 종가89.60
일중 범위89.38 - 90.88
52주 범위54.11 - 91.96
애널리스트Strong Buy
목표주가94 (3.72%)
배당n/a
배당락일n/a

DXCM 소개

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions;...

[더 보기]
산업 Medical Devices
섹터 Healthcare
IPO 일자 Apr 14, 2005
직원 수 11,000
상장 거래소 NasdaqGS
티커 DXCM
웹사이트 https://www.dexcom.com
전체 기업 정보

재무 실적

2025년 DexCom의 매출은 4.66B로, 전년 4.03B 대비 15.6% 증가했습니다. 순이익은 836.3M로, 45.14% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 25명의 투자의견을 종합하면 DXCM 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 94로, 최근 주가 대비 3.72% 상승 여력입니다.

주가 전망

어닝 서프라이즈

DexCom가 Jul 30, 2026에 분기 실적을 발표했습니다:
  • 매출 $1.31B 예상치 하회 $0, 및 13.08% 전년 대비 성장.
  • EPS 0.7 예상치 상회 0.09, 및 45.83% 전년 대비 성장.

    • 다음 실적 발표

    DexCom Inc.의 실적 발표 예정일은 Oct 29, 2026, 장 마감 후입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1일 전 · Simply Wall St.

    DexCom (DXCM) Stock May Trade At A 37% Discount On Cash Flow

    DexCom stock has gained 33.4% year to date, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to meaningful upside while the broade...

    news image

    1일 전 · Simply Wall St.

    DexCom (DXCM) Rebounds On Growth Hopes, Does It Look Fully Valued?

    DexCom stock reacts to recent performance and fundamentals DexCom (DXCM) has attracted investor attention after a recent share price move, with the stock closing at US$89.75. The company’s returns ove...

    news image

    2일 전 · Simply Wall St.

    DexCom (DXCM) Stock Sees Modest Fair Value Lift After Q2 And Clinical Updates

    DexCom’s latest analyst work shows a modest lift in the modelled fair value, with the price target figure moving from US$91.64 to US$94.12. This adjustment sits alongside mixed analyst commentary that...

    news image

    2일 전 · StockStory

    1 Surging Stock Worth Your Attention and 2 We Question

    Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage ...

    news image

    3일 전 · StockStory

    1 Growth Stock to Stash and 2 We Brush Off

    Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishm...

    2 페이지 중 1